


PHARMACEUTICAL 2023

Aquestive

Aquestive Therapeutics Inc. Rank 396 of 446





PHARMACEUTICAL 2023



Aquestive Therapeutics Inc. Rank 396 of 446

The relative strengths and weaknesses of Aquestive Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aquestive Therapeutics Inc. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 30% points. The greatest weakness of Aquestive Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 154% points.

The company's Economic Capital Ratio, given in the ranking table, is -222%, being 265% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	39,888
Cost of Goods Sold	0
Intangible Assets	1,435
Liabilities, Current	39,528
Liabilities, Non-Current	38,536
Other Assets	11,662
Other Compr. Net Income	0
Other Expenses	31,829
Other Liabilities	97,560
Other Net Income	0
Other Revenues	47,779
Property and Equipment	4,085
Research and Development	17,481
Selling, General and Administrative Expense	52,879

Output Variable	Value in 1000 USD
Assets	57,070
Liabilities	175,624
Expenses	102,189
Revenues	47,779
Stockholders Equity	-118,554
Net Income	-54,410
Comprehensive Net Income	-54,410
Economic Capital Ratio	-222%

